Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters.

Asjad HMM, Nasrollahi-Shirazi S, Sucic S, Freissmuth M, Nanoff C.

Int J Mol Sci. 2017 Nov 14;18(11). pii: E2416. doi: 10.3390/ijms18112416. Review.

2.

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

Yang Q, Puhm F, Freissmuth M, Nanoff C.

Cancer Chemother Pharmacol. 2017 Oct;80(4):673-684. doi: 10.1007/s00280-017-3390-x. Epub 2017 Aug 4.

3.

The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.

Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1732-1741. doi: 10.1007/s00259-017-3724-2. Epub 2017 May 29.

4.

Comparison of the β-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions.

Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C.

J Pharmacol Exp Ther. 2016 Oct;359(1):73-81. doi: 10.1124/jpet.116.232884. Epub 2016 Jul 22.

5.

Chaperoning of the A1-adenosine receptor by endogenous adenosine - an extension of the retaliatory metabolite concept.

Kusek J, Yang Q, Witek M, Gruber CW, Nanoff C, Freissmuth M.

Mol Pharmacol. 2015 Jan;87(1):39-51. doi: 10.1124/mol.114.094045. Epub 2014 Oct 29.

6.

A two-state model for the diffusion of the A2A adenosine receptor in hippocampal neurons: agonist-induced switch to slow mobility is modified by synapse-associated protein 102 (SAP102).

Thurner P, Gsandtner I, Kudlacek O, Choquet D, Nanoff C, Freissmuth M, Zezula J.

J Biol Chem. 2014 Mar 28;289(13):9263-74. doi: 10.1074/jbc.M113.505685. Epub 2014 Feb 7.

7.

Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor.

Bergmayr C, Thurner P, Keuerleber S, Kudlacek O, Nanoff C, Freissmuth M, Gruber CW.

J Biol Chem. 2013 Oct 4;288(40):28831-44. doi: 10.1074/jbc.M113.464776. Epub 2013 Aug 21.

8.

ER-bound steps in the biosynthesis of G protein-coupled receptors.

Nanoff C, Freissmuth M.

Subcell Biochem. 2012;63:1-21. doi: 10.1007/978-94-007-4765-4_1. Review.

PMID:
23161130
9.

Constitutive activity of the A2A adenosine receptor and compartmentalised cyclic AMP signalling fine-tune noradrenaline release.

Ibrisimovic E, Drobny H, Yang Q, Höfer T, Boehm S, Nanoff C, Schicker K.

Purinergic Signal. 2012 Dec;8(4):677-92. doi: 10.1007/s11302-012-9298-3. Epub 2012 Apr 5.

10.

The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine.

Sommerauer C, Rebernik P, Reither H, Nanoff C, Pifl C.

Neuropharmacology. 2012 Mar;62(4):1708-16. doi: 10.1016/j.neuropharm.2011.11.017. Epub 2011 Dec 6.

PMID:
22155208
11.

Pharmacochaperoning of the A1 adenosine receptor is contingent on the endoplasmic reticulum.

Málaga-Diéguez L, Yang Q, Bauer J, Pankevych H, Freissmuth M, Nanoff C.

Mol Pharmacol. 2010 Jun;77(6):940-52. doi: 10.1124/mol.110.063511. Epub 2010 Mar 10.

12.
13.

The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor.

Milojevic T, Reiterer V, Stefan E, Korkhov VM, Dorostkar MM, Ducza E, Ogris E, Boehm S, Freissmuth M, Nanoff C.

Mol Pharmacol. 2006 Apr;69(4):1083-94. Epub 2005 Dec 9.

14.

The carboxyl terminus of the Galpha-subunit is the latch for triggered activation of heterotrimeric G proteins.

Nanoff C, Koppensteiner R, Yang Q, Fuerst E, Ahorn H, Freissmuth M.

Mol Pharmacol. 2006 Jan;69(1):397-405. Epub 2005 Oct 6.

15.

Covalent modification of G-proteins by affinity labeling.

Hohenegger M, Freissmuth M, Nanoff C.

Methods Mol Biol. 2004;259:183-95.

PMID:
15250493
16.

The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.

Kudlacek O, Just H, Korkhov VM, Vartian N, Klinger M, Pankevych H, Yang Q, Nanoff C, Freissmuth M, Boehm S.

Neuropsychopharmacology. 2003 Jul;28(7):1317-27. Epub 2003 Apr 30.

17.

Truncation of the A1 adenosine receptor reveals distinct roles of the membrane-proximal carboxyl terminus in receptor folding and G protein coupling.

Pankevych H, Korkhov V, Freissmuth M, Nanoff C.

J Biol Chem. 2003 Aug 8;278(32):30283-93. Epub 2003 May 22.

18.

Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation.

Klinger M, Kuhn M, Just H, Stefan E, Palmer T, Freissmuth M, Nanoff C.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Oct;366(4):287-98. Epub 2002 Aug 28.

PMID:
12237741
19.

Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain.

Kudlacek O, Waldhoer M, Kassack MU, Nickel P, Salmi JI, Freissmuth M, Nanoff C.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):8-16. Epub 2001 Nov 7.

PMID:
11862328
20.

Adenosine receptors: G protein-mediated signalling and the role of accessory proteins.

Klinger M, Freissmuth M, Nanoff C.

Cell Signal. 2002 Feb;14(2):99-108. Review.

PMID:
11781133
21.

Development of Gs-selective inhibitory compounds.

Nanoff C, Kudlacek O, Freissmuth M.

Methods Enzymol. 2002;344:469-80. No abstract available.

PMID:
11771404
22.

Mapping of calmodulin and Gbetagamma binding domains within the C-terminal region of the metabotropic glutamate receptor 7A.

El Far O, Bofill-Cardona E, Airas JM, O'Connor V, Boehm S, Freissmuth M, Nanoff C, Betz H.

J Biol Chem. 2001 Aug 17;276(33):30662-9. Epub 2001 Jun 6.

23.

Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites.

Klinger M, Bofill-Cardona E, Mayer B, Nanoff C, Freissmuth M, Hohenegger M.

Biochem J. 2001 May 1;355(Pt 3):827-33.

24.

Inhibition of adenylyl and guanylyl cyclase isoforms by the antiviral drug foscarnet.

Kudlacek O, Mitterauer T, Nanoff C, Hohenegger M, Tang WJ, Freissmuth M, Kleuss C.

J Biol Chem. 2001 Feb 2;276(5):3010-6. Epub 2000 Oct 24.

25.

Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch.

Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C.

J Biol Chem. 2000 Oct 20;275(42):32672-80.

26.

Two different signaling mechanisms involved in the excitation of rat sympathetic neurons by uridine nucleotides.

Bofill-Cardona E, Vartian N, Nanoff C, Freissmuth M, Boehm S.

Mol Pharmacol. 2000 Jun;57(6):1165-72.

27.

G protein-dependent signalling and ageing.

Roka F, Freissmuth M, Nanoff C.

Exp Gerontol. 2000 Mar;35(2):133-43. Review. No abstract available.

PMID:
10767574
28.

Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins.

Brydon L, Roka F, Petit L, de Coppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD, Jockers R.

Mol Endocrinol. 1999 Dec;13(12):2025-38.

PMID:
10598579
29.

Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling.

O'Connor V, El Far O, Bofill-Cardona E, Nanoff C, Freissmuth M, Karschin A, Airas JM, Betz H, Boehm S.

Science. 1999 Nov 5;286(5442):1180-4.

30.

Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity.

Roka F, Brydon L, Waldhoer M, Strosberg AD, Freissmuth M, Jockers R, Nanoff C.

Mol Pharmacol. 1999 Nov;56(5):1014-24.

31.

Kinetics of ternary complex formation with fusion proteins composed of the A(1)-adenosine receptor and G protein alpha-subunits.

Waldhoer M, Wise A, Milligan G, Freissmuth M, Nanoff C.

J Biol Chem. 1999 Oct 22;274(43):30571-9.

32.

Metal-dependent nucleotide binding to the Escherichia coli rotamase SlyD.

Mitterauer T, Nanoff C, Ahorn H, Freissmuth M, Hohenegger M.

Biochem J. 1999 Aug 15;342 ( Pt 1):33-9.

33.

G protein antagonists.

Freissmuth M, Waldhoer M, Bofill-Cardona E, Nanoff C.

Trends Pharmacol Sci. 1999 Jun;20(6):237-45. Review.

PMID:
10366866
34.

G proteins as drug targets.

Höller C, Freissmuth M, Nanoff C.

Cell Mol Life Sci. 1999 Feb;55(2):257-70. Review.

PMID:
10188585
35.

The C2 catalytic domain of adenylyl cyclase contains the second metal ion (Mn2+) binding site.

Mitterauer T, Hohenegger M, Tang WJ, Nanoff C, Freissmuth M.

Biochemistry. 1998 Nov 17;37(46):16183-91.

PMID:
9819210
36.

Differential uncoupling of A1 adenosine and D2 dopamine receptors by suramin and didemethylated suramin (NF037).

Waldhoer M, Bofill-Cardona E, Milligan G, Freissmuth M, Nanoff C.

Mol Pharmacol. 1998 May;53(5):808-18.

37.

Gsalpha-selective G protein antagonists.

Hohenegger M, Waldhoer M, Beindl W, Böing B, Kreimeyer A, Nickel P, Nanoff C, Freissmuth M.

Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):346-51.

38.
39.

Coupling cofactor--a novel regulatory component in G protein-mediated signalling?

Nanoff C, Freissmuth M.

Physiol Res. 1997;46(2):79-87. Review.

PMID:
9727497
40.

Covalent modification of G proteins by affinity labeling.

Hohenegger M, Freissmuth M, Nanoff C.

Methods Mol Biol. 1997;83:179-90. Review. No abstract available.

PMID:
9210145
41.

Inhibition of receptor/G protein coupling by suramin analogues.

Beindl W, Mitterauer T, Hohenegger M, Ijzerman AP, Nanoff C, Freissmuth M.

Mol Pharmacol. 1996 Aug;50(2):415-23.

PMID:
8700151
42.

Suramin analogues as subtype-selective G protein inhibitors.

Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, Hohenegger M, Nanoff C.

Mol Pharmacol. 1996 Apr;49(4):602-11.

PMID:
8609887
43.
44.
45.

Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor.

Jockers R, Linder ME, Hohenegger M, Nanoff C, Bertin B, Strosberg AD, Marullo S, Freissmuth M.

J Biol Chem. 1994 Dec 23;269(51):32077-84.

47.
48.

Solubilization and characterization of the A2-adenosine receptor.

Nanoff C, Stiles GL.

J Recept Res. 1993;13(6):961-73.

PMID:
8510073

Supplemental Content

Loading ...
Support Center